Resources Contact Us Home
Methods of inhibiting IL-2 production by T cells by administering 7C10 and 16C10 CD80-specific antibodies

Image Number 12 for United States Patent #7491393.

The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (CD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signalling. These antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.

  Recently Added Patents
Steplessly adjustable cymbal locating device
Adjustable draw bar for trailer hitches
Compound containing a carbon or an oxygen isotope, preparation and use thereof, and composition comprising thereof
Apparatus for tuning a musical instrument, and a related instrument
Using storage cells to perform computation
Shoe outsole with a surface ornamentation contrast
Housing for gas flow indicator
  Randomly Featured Patents
Isolation platform assembly for supporting an instrumentation payload
Lubricating device for outboard motor
Multiple-disc clutch for tractor PTO shaft
Sensor device and method
Combined cigarette case and ashtray
Pressure relief check valve arrangement for differential assembly
Digital camera
Exothermic reaction system
Video cassette recorder
System, method, and computer program product for controlling energy consumption in data centers